Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.

Molina-Arcas M, Moore C, Rana S, van Maldegem F, Mugarza E, Romero-Clavijo P, Herbert E, Horswell S, Li LS, Janes MR, Hancock DC, Downward J.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaaw7999. doi: 10.1126/scitranslmed.aaw7999.

PMID:
31534020
2.

ATMIN Is a Tumor Suppressor Gene in Lung Adenocarcinoma.

Foster H, Ruiz EJ, Moore C, Stamp GWH, Nye EL, Li N, Pan Y, He Y, Downward J, Behrens A.

Cancer Res. 2019 Oct 15;79(20):5159-5166. doi: 10.1158/0008-5472.CAN-19-0647. Epub 2019 Sep 3.

PMID:
31481498
3.

Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis.

Hill C, Li J, Liu D, Conforti F, Brereton CJ, Yao L, Zhou Y, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Ottensmeier CH, Steele AJ, Downward J, Richeldi L, Lu X, Davies DE, Jones MG, Wang Y.

Cell Death Dis. 2019 Aug 7;10(8):591. doi: 10.1038/s41419-019-1820-x.

4.

RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.

Lionarons DA, Hancock DC, Rana S, East P, Moore C, Murillo MM, Carvalho J, Spencer-Dene B, Herbert E, Stamp G, Damry D, Calado DP, Rosewell I, Fritsch R, Neubig RR, Molina-Arcas M, Downward J.

Cancer Cell. 2019 Jul 8;36(1):68-83.e9. doi: 10.1016/j.ccell.2019.05.015. Epub 2019 Jun 27.

5.

SGLT1 is required for the survival of triple-negative breast cancer cells via potentiation of EGFR activity.

Liu H, Ertay A, Peng P, Li J, Liu D, Xiong H, Zou Y, Qiu H, Hancock D, Yuan X, Huang WC, Ewing RM, Downward J, Wang Y.

Mol Oncol. 2019 Sep;13(9):1874-1886. doi: 10.1002/1878-0261.12530. Epub 2019 Jun 14.

6.

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.

Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, Areso Zubiaur I, El-Bahrawy MA, Hynds RE, Lei W, Molina-Arcas M, Downward J, Rodriguez-Viciana P.

Nat Commun. 2019 Jun 10;10(1):2532. doi: 10.1038/s41467-019-10367-x.

7.

Autophagy inhibition specifically promotes epithelial-mesenchymal transition and invasion in RAS-mutated cancer cells.

Wang Y, Xiong H, Liu D, Hill C, Ertay A, Li J, Zou Y, Miller P, White E, Downward J, Goldin RD, Yuan X, Lu X.

Autophagy. 2019 May;15(5):886-899. doi: 10.1080/15548627.2019.1569912. Epub 2019 Feb 20.

8.

Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer.

Murillo MM, Rana S, Spencer-Dene B, Nye E, Stamp G, Downward J.

Cell Rep. 2018 Dec 26;25(13):3545-3553.e2. doi: 10.1016/j.celrep.2018.12.003.

9.

Quantitation of class IA PI3Ks in mice reveals p110-free-p85s and isoform-selective subunit associations and recruitment to receptors.

Tsolakos N, Durrant TN, Chessa T, Suire SM, Oxley D, Kulkarni S, Downward J, Perisic O, Williams RL, Stephens L, Hawkins PT.

Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12176-12181. doi: 10.1073/pnas.1803446115. Epub 2018 Nov 15.

10.

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y.

Cell Death Differ. 2019 May;26(5):943-957. doi: 10.1038/s41418-018-0175-7. Epub 2018 Jul 26.

11.

AKT signalling selectively regulates PINK1 mitophagy in SHSY5Y cells and human iPSC-derived neurons.

Soutar MPM, Kempthorne L, Miyakawa S, Annuario E, Melandri D, Harley J, O'Sullivan GA, Wray S, Hancock DC, Cookson MR, Downward J, Carlton M, Plun-Favreau H.

Sci Rep. 2018 Jun 11;8(1):8855. doi: 10.1038/s41598-018-26949-6.

12.

The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma.

Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher DW, Peck B, Schulze A.

Oncogene. 2018 Oct;37(40):5435-5450. doi: 10.1038/s41388-018-0315-z. Epub 2018 Jun 5.

13.

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.

Coelho MA, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J.

Immunity. 2017 Dec 19;47(6):1083-1099.e6. doi: 10.1016/j.immuni.2017.11.016. Epub 2017 Dec 12.

14.

An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.

Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y.

EMBO Mol Med. 2018 Feb;10(2):294-308. doi: 10.15252/emmm.201708076.

15.

Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor.

Mathew G, Hannan A, Hertzler-Schaefer K, Wang F, Feng GS, Zhong J, Zhao JJ, Downward J, Zhang X.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13156-13161. Epub 2016 Oct 31.

16.

Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.

Li H, Stokes W, Chater E, Roy R, de Bruin E, Hu Y, Liu Z, Smit EF, Heynen GJ, Downward J, Seckl MJ, Wang Y, Tang H, Pardo OE.

Cell Discov. 2016 Sep 27;2:16031. eCollection 2016.

17.

HF-Free Boc Synthesis of Peptide Thioesters for Ligation and Cyclization.

Raz R, Burlina F, Ismail M, Downward J, Li J, Smerdon SJ, Quibell M, White PD, Offer J.

Angew Chem Int Ed Engl. 2016 Oct 10;55(42):13174-13179. doi: 10.1002/anie.201607657.

18.

Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells.

Houslay DM, Anderson KE, Chessa T, Kulkarni S, Fritsch R, Downward J, Backer JM, Stephens LR, Hawkins PT.

Sci Signal. 2016 Aug 16;9(441):ra82. doi: 10.1126/scisignal.aae0453.

19.

RAS signalling through PI3-Kinase controls cell migration via modulation of Reelin expression.

Castellano E, Molina-Arcas M, Krygowska AA, East P, Warne P, Nicol A, Downward J.

Nat Commun. 2016 Apr 13;7:11245. doi: 10.1038/ncomms11245.

20.

Tumour-suppression function of KLF12 through regulation of anoikis.

Godin-Heymann N, Brabetz S, Murillo MM, Saponaro M, Santos CR, Lobley A, East P, Chakravarty P, Matthews N, Kelly G, Jordan S, Castellano E, Downward J.

Oncogene. 2016 Jun 23;35(25):3324-34. doi: 10.1038/onc.2015.394. Epub 2015 Oct 12.

21.

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.

Pender A, Garcia-Murillas I, Rana S, Cutts RJ, Kelly G, Fenwick K, Kozarewa I, Gonzalez de Castro D, Bhosle J, O'Brien M, Turner NC, Popat S, Downward J.

PLoS One. 2015 Sep 28;10(9):e0139074. doi: 10.1371/journal.pone.0139074. eCollection 2015.

22.

Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer.

Sheridan C, Downward J.

Curr Protoc Pharmacol. 2015 Sep 1;70:14.35.1-16. doi: 10.1002/0471141755.ph1435s70. Review.

PMID:
26331885
23.

Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.

Mancini M, Gaborit N, Lindzen M, Salame TM, Dall'Ora M, Sevilla-Sharon M, Abdul-Hai A, Downward J, Yarden Y.

Sci Signal. 2015 Jun 2;8(379):ra53. doi: 10.1126/scisignal.aaa0725.

PMID:
26038598
24.

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward J.

Clin Cancer Res. 2015 Apr 15;21(8):1802-9. doi: 10.1158/1078-0432.CCR-14-2180. Review.

25.

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

Smith D, Armenteros E, Percy L, Kumar M, Lach A, Herledan G, Stubbs M, Downward J, Yong K.

Br J Haematol. 2015 Jun;169(6):905-8. doi: 10.1111/bjh.13258. Epub 2015 Jan 12. No abstract available.

PMID:
25580780
26.

ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1.

Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto MS, Sibson NR, Salter V, Fritzsche F, Turnquist C, Koch S, Zak J, Zhong S, Wu G, Liang A, Olofsen PA, Moch H, Hancock DC, Downward J, Goldin RD, Zhao J, Tong X, Guo Y, Lu X.

Nat Cell Biol. 2014 Nov;16(11):1092-104. doi: 10.1038/ncb3050. Epub 2014 Oct 26.

PMID:
25344754
27.

Guidelines for the use of cell lines in biomedical research.

Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, Knezevic I, Lovell-Badge R, Masters JR, Meredith J, Stacey GN, Thraves P, Vias M; Cancer Research UK.

Br J Cancer. 2014 Sep 9;111(6):1021-46. doi: 10.1038/bjc.2014.166. Epub 2014 Aug 12.

28.

RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.

Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, Downward J.

J Clin Invest. 2014 Aug;124(8):3601-11. doi: 10.1172/JCI74134. Epub 2014 Jul 8.

29.

Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.

Endesfelder D, Burrell R, Kanu N, McGranahan N, Howell M, Parker PJ, Downward J, Swanton C, Kschischo M.

Cancer Res. 2014 Sep 1;74(17):4853-4863. doi: 10.1158/0008-5472.CAN-13-2664. Epub 2014 Jun 26.

30.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

de Bruin EC, Cowell C, Warne PH, Jiang M, Saunders RE, Melnick MA, Gettinger S, Walther Z, Wurtz A, Heynen GJ, Heideman DA, Gómez-Román J, García-Castaño A, Gong Y, Ladanyi M, Varmus H, Bernards R, Smit EF, Politi K, Downward J.

Cancer Discov. 2014 May;4(5):606-19. doi: 10.1158/2159-8290.CD-13-0741. Epub 2014 Feb 17.

31.

RAS's cloak of invincibility slips at last?

Downward J.

Cancer Cell. 2014 Jan 13;25(1):5-6. doi: 10.1016/j.ccr.2013.12.016.

32.

HMGA2 functions as a competing endogenous RNA to promote lung cancer progression.

Kumar MS, Armenteros-Monterroso E, East P, Chakravorty P, Matthews N, Winslow MM, Downward J.

Nature. 2014 Jan 9;505(7482):212-7. doi: 10.1038/nature12785. Epub 2013 Dec 4. Retraction in: Nature. 2015 Jul 16;523(7560):370.

33.

Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance.

Castellano E, Sheridan C, Thin MZ, Nye E, Spencer-Dene B, Diefenbacher ME, Moore C, Kumar MS, Murillo MM, Grönroos E, Lassailly F, Stamp G, Downward J.

Cancer Cell. 2013 Nov 11;24(5):617-30. doi: 10.1016/j.ccr.2013.09.012.

34.

Regulation of polarized morphogenesis by protein kinase C iota in oncogenic epithelial spheroids.

Linch M, Sanz-Garcia M, Rosse C, Riou P, Peel N, Madsen CD, Sahai E, Downward J, Khwaja A, Dillon C, Roffey J, Cameron AJ, Parker PJ.

Carcinogenesis. 2014 Feb;35(2):396-406. doi: 10.1093/carcin/bgt313. Epub 2013 Sep 26.

35.

SnapShot: Class I PI3K isoform signaling.

Fritsch R, Downward J.

Cell. 2013 Aug 15;154(4):940-940.e1. doi: 10.1016/j.cell.2013.07.045. No abstract available.

36.

RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms.

Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS, Diefenbacher M, Stamp G, Downward J.

Cell. 2013 May 23;153(5):1050-63. doi: 10.1016/j.cell.2013.04.031.

37.

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J.

Clin Cancer Res. 2013 Jul 1;19(13):3533-44. doi: 10.1158/1078-0432.CCR-12-3815. Epub 2013 May 14.

38.

Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.

Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J.

Cancer Discov. 2013 May;3(5):548-63. doi: 10.1158/2159-8290.CD-12-0446. Epub 2013 Mar 1.

39.

Inhibiting the RAS-PI3K pathway in cancer therapy.

Sheridan C, Downward J.

Enzymes. 2013;34 Pt. B:107-36. doi: 10.1016/B978-0-12-420146-0.00005-6. Epub 2013 Nov 7. Review.

PMID:
25034102
40.

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer.

Weigelt B, Downward J.

Front Oncol. 2012 Aug 31;2:109. doi: 10.3389/fonc.2012.00109. eCollection 2012.

41.

Frank-ter Haar syndrome protein Tks4 regulates epidermal growth factor-dependent cell migration.

Bögel G, Gujdár A, Geiszt M, Lányi Á, Fekete A, Sipeki S, Downward J, Buday L.

J Biol Chem. 2012 Sep 7;287(37):31321-9. doi: 10.1074/jbc.M111.324897. Epub 2012 Jul 24.

42.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne PH, Kuznetsov H, Kelly G, Saunders B, Howell M, Downward J, Hancock DC.

Cell Res. 2012 Aug;22(8):1227-45. doi: 10.1038/cr.2012.82. Epub 2012 May 22.

43.

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J.

Cell. 2012 Apr 27;149(3):642-55. doi: 10.1016/j.cell.2012.02.059.

44.

Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C.

N Engl J Med. 2012 Mar 8;366(10):883-892. doi: 10.1056/NEJMoa1113205. Erratum in: N Engl J Med. 2012 Sep 6;367(10):976.

45.

How to fool a wonder drug: truncate and dimerize.

Molina-Arcas M, Downward J.

Cancer Cell. 2012 Jan 17;21(1):7-9. doi: 10.1016/j.ccr.2011.12.017.

46.
47.

Assessing cell size and cell cycle regulation in cells with altered TOR activity.

Cully M, Downward J.

Methods Mol Biol. 2012;821:227-37. doi: 10.1007/978-1-61779-430-8_13.

PMID:
22125068
48.

CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploid-specific cancer cell death through autophagy induction.

Lee AJ, Roylance R, Sander J, Gorman P, Endesfelder D, Kschischo M, Jones NP, East P, Nicke B, Spassieva S, Obeid LM, Birkbak NJ, Szallasi Z, McKnight NC, Rowan AJ, Speirs V, Hanby AM, Downward J, Tooze SA, Swanton C.

J Pathol. 2012 Feb;226(3):482-94. doi: 10.1002/path.2998. Epub 2011 Oct 19.

PMID:
21953249
49.

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.

Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94. doi: 10.1158/1055-9965.EPI-11-0343. Epub 2011 Jul 22.

50.

RAS Interaction with PI3K: More Than Just Another Effector Pathway.

Castellano E, Downward J.

Genes Cancer. 2011 Mar;2(3):261-74. doi: 10.1177/1947601911408079.

Supplemental Content

Loading ...
Support Center